AEON Biopharma (AEON) Announces 1:72 Reverse Share Split

AEON Biopharma, Inc. (NYSE: AEON) today announced that the Company’s Board of Directors approved a 1-for-72 reverse stock split (the “Reverse Stock Split”) of the Company’s common stock, par value $0.0001 (the “Common Stock”), to increase the selling price of the Company’s Common Stock in order to maintain compliance with the requirements and policies of the NYSE American LLC (the “NYSE American”).

The Reverse Stock Split will take legal effect at 12:01 A.M. Eastern Time on February 26, 2025, and the Company's Common Stock will open for trading on the NYSE American on February 26, 2025, on a post-split basis, under the existing ticker symbol "AEON" but with a new CUSIP number [00791X 209].

At the Company’s Special Meeting of Stockholders (the “Special Meeting”) held on February 24, 2025, the Company’s stockholders approved a proposal to amend the Company’s certificate of incorporation to effect a reverse stock split of its Common Stock at a ratio of between 1-for-5 to 1-for-150, with the ratio within such range to be determined at the discretion of the Company’s Board. Following the Special Meeting, the Board approved a final split ratio of 1-for-72. Following the Reverse Stock Split, the ownership percentage of each stockholder will remain unchanged, other than with respect to fractional shares. No fractional shares will be issued in connection with the Reverse Stock Split, with any fractional shares instead being rounded up to the nearest whole share.

Additional details regarding the Company’s Reverse Stock Split can be found in the Current Report on Form 8-K filed on February 24, 2025 with the Securities and Exchange Commission (the “SEC”).

You May Also Be Interested In

• Energy Vault’s 100 MW AI Infrastructure Project in Sardinia Receives Italian Government Designation as Project of Pre-Eminent National Strategic Interest
• BlossomHill to present BH-30643 trial data at lung cancer conference
• XTEND deploys XOS-powered AtlasROVER to Asia-Pacific customer